INFI

Infinity Pharmaceuticals, Inc. (INFI) | Rumor.io

Infinity Pharmaceuticals

INFI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about INFI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 8

$INFI is building the core infrastructure for AI-native Web3, including loop farming, agent-based DeFi, and one-click strategies.
The project is focused on real innovation and utility, rather than fake hype, and is changing the game in DeFi with its accessible and powerful approach.
$INFI is enabling a new kind of coordination in DeFi, allowing users to own their strategy, plug into the network, and grow with the ecosystem.

Generated by AI

Sentiment

Of the messages about INFI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +10
Bearish	—	—	—	0% -10

Bullish· Sep 30

$INFI has been officially registered as a business in the UK, adhering to high levels of transparency and corporate governance.
$INFI's utility is backed by real infrastructure, with the company meeting with major providers to kickstart their network in the UK and UAE.
$INFI is undervalued and has the potential to supercharge, with a recent pullback providing an opportunity to buy in and upcoming updates expected to drive growth.

Bearish· Jul 27

Management's actions are a concern, rather than the data itself, which may limit the downside.
The company's cash position is around $1.3B, but the market is valuing it at over $50M more than that.
The price drop is seen as an overreaction to the data, with some believing it's due to market manipulation rather than the data itself.

Generated by AI

Topics

Of the messages about INFI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Earnings· Nov 7

Infinity Pharmaceuticals beat earnings estimates by $0.07.
The company missed revenue expectations.
The earnings report was released pre-market.

Analysts· Jun 15

Infinity Pharmaceuticals was downgraded by several analysts, including Morgan Stanley, Jefferies, William Blair, RBC Capital Markets, and Wells Fargo.
Downgrades were due to various reasons, including a price target cut from $13 to $1 at Morgan Stanley, and a price target cut from $12 to $2 at RBC Capital Markets.
Analysts downgraded Infinity Pharmaceuticals to various ratings, including equal-weight, hold, market perform, and sector perform, with price targets ranging from $1 to $2.

Announcements· Feb 23

MEI Pharma ($MEIP) and Infinity Pharmaceuticals ($INFI) have entered into a definitive merger agreement to form a company focused on three clinical-stage oncology drug candidates.
The combined company's pipeline will be led by a Phase 2 trial in head and neck squamous cell carcinoma (HNSCC).
The merger is an all-stock transaction, with MEI Pharma as the majority holder, and is expected to advance three promising clinical oncology candidates.

Technical Analysis· Mar 18

INFI has broken above the 50-day moving average (DMA) premarket.
The stock is now above both the 20-day and 50-day moving averages.
This technical development is seen as a bullish sign.

Generated by AI

Community

Of the messages about INFI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	30%
Newcomers	—	—	—	70%

Regulars· Aug 8

Shares of Infinity Pharmaceuticals ($INFI) have increased by more than 64% since the last tweet, and regulars are wondering if it will continue to gain.
The stock has experienced a "dynamo gap up" with a relatively large volume, and is currently trading at $0.10, up 15% since the previous trading day close.
$INFI is down 1.4% in the last 5 minutes, with 21 stocks up more than 3% in the same time frame, and the top gainer is up 19.1% in the last 5 minutes.

Newcomers· Aug 8

$INFI is experiencing a significant rise of 71.28% to $0.15, with a notable accumulated volume.
New investors are keeping an eye on $INFI for its potential, possibly due to recent buying pressure on small caps.
A setup for $INFI is being watched, as higher buying pressure on small caps is currently being seen.

Generated by AI

Also Discussed

Investors talking about INFI also mention

#	Name	Attention
1	Mereo BioPharma Group plc ADRMREO	0.01%-0.01
2	MRNS - Marinus Pharmaceuticals, Inc.	——
3	Celldex Therapeutics IncCLDX	0%+0
4	NFNT - Infinite Acquisition Corp.	——
5	Chicago Rivet & Machine Co. Common StockCVR	0%0
6	JNCE - Jounce Therapeutics, Inc.	——
7	Verastem Inc.VSTM	0%0
8	IMPL - Impel Pharmaceuticals Inc.	——
9	ZW Data Action Technologies Inc.CNET	0%0
10	ONCT - Oncternal Therapeutics, Inc.	——